Securities code: 600196 stock abbreviation: Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) No.: lin2022-015 bond Code: 143020 bond abbreviation: 17 Fuyao 01
Bond Code: 143422 bond abbreviation: 18 Fuyao 01
Bond Code: 155067 bond abbreviation: 18 Fuyao 02
Bond Code: 155068 bond abbreviation: 18 Fuyao 03
Bond Code: 175708 bond abbreviation: 21 Fuyao 01
Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd
Announcement on the progress of drug clinical trials of holding subsidiaries
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
1、 Overview
Recently, Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Jiangsu Wanbang”), a holding subsidiary of Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd. (hereinafter referred to as “the company”), has used furetinib succinate capsule (original project code saf-189, hereinafter referred to as “the new drug”) for the treatment of non-small cell lung cancer in China (excluding Hong Kong, Macao and Taiwan, the same below) (ALK +) start phase III clinical trial.
2、 Research status of the new drug
The new drug is an innovative small molecule chemical drug, which is intended to be mainly used in tumor treatment. Chongqing fuchuang Pharmaceutical Research Co., Ltd., a holding subsidiary of the company, and Shanghai Institute of pharmaceutical research, Chinese Academy of Sciences jointly conducted preclinical research on the new drug, and exclusively licensed Jiangsu Wanbang to carry out exclusive development (including but not limited to clinical trial, listing registration, etc.) and commercialization of the new drug in China.
As of the date of this announcement, the drugs for non-small cell lung cancer (ALK +) listed in China mainly include kezotinib capsule of preferred Inc., seretinib capsule of Novartis AG, Betta Pharmaceuticals Co.Ltd(300558) ensatinib hydrochloride capsule and Roche aletinib hydrochloride capsule. According to the iqvia CHPA data (provided by iqvia, iqvia is the world’s leading provider of professional information and strategic consulting services for the medical and health industry; iqvia CHPA data represents the drug sales market of hospitals with more than 100 beds in China, and the actual sales situation of different drugs may differ from iqvia CHPA data to varying degrees due to their different sales channel layout), In 2020 and the first half of 2021, the sales of these drugs in China were about RMB 1.825 billion and RMB 1.145 billion respectively.
As of December 2021, the group’s cumulative R & D investment in the new drug at this stage was RMB 178.97 million (Unaudited).
3、 Risk tips
According to the experience of new drug research and development, there are certain risks in new drug research and development. For example, clinical trials may be terminated due to problems such as safety and / or effectiveness.
According to the requirements of relevant Chinese laws and regulations, the new drug can only be listed after a series of clinical studies are carried out in China and approved by the national drug evaluation department.
The R & D and listing of new drugs is a long-term work, and there are many uncertain factors. Please pay attention to the investment risks.
It is hereby announced.
Board of directors of Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd. January 19, 2002
